Business
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro’s platform for developing dual-payload ADCs SOUTH SAN FRANCISCO, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Sutro Biopha
About this update from Sutro Biopharma, Inc.
[{"type":"image","alt":"Sutro Biopharma, Inc.","displaySize":"","headline":null,"caption":"Sutro Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":186,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/ca5877b05c127c1dc6a01374ae1f5ab8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s..3K.B9bkmIYuacOe7alw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEwNg--/https://media.zenfs.com/en/globenewswire.com/ca5877b05c127c1dc6a01374ae1f5ab8","width":186,"height":55}},"lazy":false},{"type":"text","content":"STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs","length":161,"tagName":"p"},{"type":"text","content":"STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models","length":98,"tagName":"p"},{"type":"text","content":"Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro’s platform for developing dual-payload ADCs","length":162,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced promising preclinical data across its pipeline of next- generation ADCs in five posters and one oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. Of note, results from a preclinical study of STRO-004, its DAR8 Topo1 ADC targeting Tissue Factor (TF), were reviewed today in an oral presentation titled “STRO-004, an exatecan-based next-generation tissue factor (TF)-targeted ADC, demonstrates superior efficacy across TF-expressing solid tumors in a comprehensive single-mouse PDX trial.”","length":781,"tagName":"p"},{"type":"text","content":"In the preclinical study, STRO-004 demonstrated robust and consistent antitumor activity across a broad range of TF-expressing solid tumor patient-derived xenograft (PDX) models, with improved efficacy compared to benchmark ADCs. At a single, clinically relevant dose of 5 mg/kg, STRO-004 achieved remarkable disease control and tumor reduction across multiple tumor types. STRO-004’s favorable tolerability, with a highe...